ImmuPharma plc
IMMPF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$28.34M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $28.34 Million |
|---|---|
| Enterprise Value | $27.64 Million |
| Annual dividend | $3.00 |
| Earnings per Share | $- |
| Beta | 1.41 |
| Outstanding Shares | - |
Return
| Return on Equity | -385.44% |
|---|---|
| Return on Assets | -226.67% |
| Return on Invested Capital | -195.42% |
Valuation & Multiples
| P/E Ratio | -3.04 |
|---|---|
| PEG | -0.74 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.76 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About ImmuPharma PLC
7 employees
CEO: Timothy Paul McCarthy
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The com...